News | October 28, 2019

Gore Receives European Approval For Cardioform ASD Occluder For Atrial Septal Defects

CE mark supported by data from the Gore ASSURED Clinical Study, demonstrating 100 percent closure success

The Gore Cardioform ASD Occluder received European CE mark clearance in early October. The device offers a percutaneous, transcatheter closure option for the ostium secundum atrial septal defects (ASDs).

October 28, 2019 — The Gore Cardioform ASD Occluder received European CE mark clearance in early October. The device offers a percutaneous, transcatheter closure option for the ostium secundum atrial septal defects (ASDs).

The Gore ASSURED Clinical Study demonstrated safety, closure and technical success that statistically achieved the primary endpoint. The new addition to the Gore portfolio extends the Gore Cardioform occluder family.

The ASD occluder’s anatomically adaptable waist conforms to the defect to close ASDs from 8 to 35 mm in diameter, including those without a retro-aortic rim, by facilitating optimal tissue ingrowth, while maintaining thrombo-resistance. The ability to retrieve and reposition the Ccardioform ASD Occluder helps ensure proper positioning and offers confident closure, the vendor said.

“Larger defects typically have a greater risk for complications, like pulmonary hypertension, right heart enlargement, or atrial fibrillation. But previously, Europe didn’t have access to the Gore Cardioform ASD Occluder for this range of defects,” said Matthew Gillespie, M.D., Children’s Hospital of Philadelphia, co-principal investigator of the ASSURED Clinical Study. “CE mark makes this soft, conformable device available for the minimally invasive treatment of a broader range of ASDs.”

The pivotal study evaluated the safety and efficacy of ASD closure using the Cardioform ASD Occluder in 125 patients with evidence of right heart volume overload demonstrating the need for defect closure. The study involved patients between the ages of 2 and 84, across 22 investigation sites, including 15 children's hospitals. The pivotal study met its safety, closure, and technical success primary endpoints.

The Cardioform ASD Occluder was recently granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of atrial septal defects and is the newest addition in Gore’s occluder portfolio. The portfolio also includes the Cardioform Septal Occluder, which is indicated for ASD closure for defects up to 17 mm and received FDA clearance in 2018 for patent foramen ovale (PFO) closure to prevent recurrent ischemic stroke. In May 2018, positive results were announced from the Gore REDUCE Clinical Study, which demonstrated the safety and efficacy of PFO closure with a Gore device plus antiplatelet therapy compared to antiplatelet therapy alone in patients with a PFO and history of cryptogenic stroke.

For more information: www.gore.com

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...